Methadone Levels in Breast Milk of Women Taking Methadone for Opiate Addiction - 2
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Feeding; Opioid-Related Disorders
Phase: N/A
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s): Lauren M. Jansson, MD, Principal Investigator, Affiliation: Johns Hopkins University
Summary
Methadone is a drug that offers significant therapeutic benefits to opiate dependent women
who are pregnant. Currently, it is the treatment of choice for this group of people. The
purpose of this study is to determine the amount of methadone in the breast milk of women who
are breastfeeding and taking methadone for opiate addiction. In addition, this study will
evaluate the effects of methadone on infant neurobehavior.
Clinical Details
Official title: Breastfeeding Among Methadone Maintained Women
Study design: Screening, Longitudinal, Case Control, Prospective Study
Detailed description:
Methadone is a drug that is commonly used to treat opiate addiction, usually as part of a
detoxification and maintenance program. Methadone offers significant therapeutic benefits to
pregnant women who are opiate dependent, and it is currently the treatment of choice for this
group of people. In general, breast milk is beneficial for infants. However, there is some
concern as to whether it is safe for women who are taking methadone to breastfeed their
babies. The purpose of this study is to determine the amount of methadone in the breast milk
of women who are breastfeeding and taking methadone for opiate addiction. In addition, this
study will evaluate the effects of methadone on infant neurobehavior.
Participants will be assigned to one of two groups: women taking methadone who will
breastfeed their babies or women taking methadone who will bottle-feed their babies. On Days
1, 2, 3, 4, 14, and 30, following infant delivery, plasma will be collected from both groups
and breast milk will be collected from the breastfeeding group. These samples will be
quantitatively analyzed for methadone. Infants will undergo neurobehavioral assessments on
Days 3, 14, and 30, following birth. Rates and severity of neonatal abstinence syndrome will
also be evaluated.
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Generally healthy methadone-maintained women electing to either exclusively breastfeed
or bottle-feed their infants for 1 month after delivery
Exclusion Criteria:
- Relapse to illicit drugs or alcohol at any time during the study
- Positive maternal or infant urine toxicology test at birth
- Serious medical or psychiatric illness requiring medication or medical intervention
- HIV infected
- Currently dependent on alcohol
- Major birth defect in the infant
- Significant medical problems in the infant, including premature birth, sepsis, or
other infections
Locations and Contacts
Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland 21224 6823, United States
Additional Information
Related publications: Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact. 2004 Feb;20(1):62-71. Review.
Starting date: November 2000
Ending date: September 2005
Last updated: August 2, 2006
|